Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644183 · ClinicalTrials.gov registry record · Phase 1
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study of Leukemia and Chronic Lymphocytic Leukemia, sponsored by Jennifer R. Brown, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06644183 is a Phase 1 study of Leukemia and Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Jennifer R. Brown, MD, PhD. The registered enrollment target is 64 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06644183, a Phase 1 study of Leukemia and Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Jennifer R. Brown, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody)
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Rituximab
- DRUG Roginolisib
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06644183
The ClinicalTrials.gov registry entry for NCT06644183 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (87% lower). The listed sponsor is Jennifer R. Brown, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT06644183 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06644183 about?
NCT06644183 is a clinical study titled "Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)". This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a nov...
What is the current status of trial NCT06644183?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2025-03-19. Estimated completion is 2032-10-01.
What conditions does trial NCT06644183 study?
This clinical trial studies the following conditions: Leukemia, Chronic Lymphocytic Leukemia, Relapsed Cancer, Refractory Leukemia, Relapsed Leukemia.
What interventions are being tested in trial NCT06644183?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG), Roginolisib (DRUG).
Who is sponsoring clinical trial NCT06644183?
This trial is sponsored by Jennifer R. Brown, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644183 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.